Francesco Bellanti | Epatologia | Research Excellence Award

Published on by Invention Awards

Assoc. Prof. Dr. Francesco Bellanti | Epatologia | Research Excellence Award

Department of Medical and Surgical Sciences, University of Foggia, Italy

Assoc. Prof. Dr. Francesco Bellanti is an Italian physician–scientist at the University of Foggia with a Medical Degree, Specialty in Internal Medicine, and a PhD in Clinical, Medical and Experimental Sciences, complemented by international training through Erasmus, postdoctoral, and visiting fellowships in Spain, France, and the UK. His research focuses on liver disease, aging, redox biology, mitochondrial dysfunction, and metabolic disorders, supported by multiple competitive grants and prestigious awards from national and European scientific societies. He has served as principal or co-investigator in several national and multicentre clinical registries and trials, including studies on diabetes, COVID-19, primary biliary cholangitis, and polypharmacy. Dr. Bellanti has extensive teaching experience across medicine, emergency medicine, and internal medicine for multiple health disciplines, with regular visiting professorships across Europe. He has been actively involved in postgraduate supervision, mentoring PhD students, medical residents, and undergraduate students in medicine, nutrition, and allied health sciences. His academic career reflects a strong integration of clinical practice, translational research, international collaboration, and long-term commitment to medical education.

Citation Metrics (Scopus)

5000
4000
3000
2000
1000
0

Citations
4122

Documents
110

h-index
35

Citations

Documents

h-index

View Scopus Profile

Featured Publications

 

Amedeo Lonardo | Epatologia | Lifetime achievement Award

Published on by Invention Awards

Dr. Amedeo Lonardo | Epatologia | Lifetime Achievement Award 

Azienda Ospedaliero-Univresitaria di Modena | Italy

Dr. Amedeo Lonardo is a distinguished medical scientist and clinician, holding specializations in Gastroenterology, Pediatrics, and Internal Medicine. He is qualified as Full Professor of Gastroenterology and Associate Professor of Internal Medicine by the Italian National Examination (2017). With a prolific academic career, he has authored 279 scientific publications that have collectively received 19,170 citations as of October 2025, reflecting his enduring influence in hepatology and metabolic research. His h-index stands at 69 (Scopus) and 78 (Google Scholar and ScholarGPS), highlighting his international research impact. Dr. Lonardo currently serves as Founding Editor and Editor-in-Chief of Metabolism and Target Organ Damage (since 2021) and Editor-in-Chief of Metabolites (since 2024), and also contributes as Associate Editor for Exploration of Medicine and as a member of the editorial boards of Liver International, Digestive and Liver Disease, Advances in Therapy, Exploration of Digestive Diseases, and Exploration of Drug Science. With over 546 editorial records and 1,342 peer review contributions documented in Web of Science, he stands among the most active academic editors in his field. His work has involved collaboration with 2,572 international co-authors, underscoring his extensive global scientific network. Dr. Lonardo’s research focuses primarily on sex differences and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD. He pioneered investigations into the influence of sex and sex hormones on fatty liver disease pathogenesis (PMIDs: 10937684, 16618516, 19347015), and expanded this domain to include endocrinological and extrahepatic implications (PMIDs: 31212642, 30084737, 30733187, 39794250, 40566760). His most influential and highly cited reviews published in The Lancet (PMID: 32828189) and Hepatology (PMID: 30924946) have shaped the modern understanding of gender-related differences in MASLD, consolidating his reputation as a global leader in hepatology and metabolic research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

Weiskirchen, R., & Lonardo, A. (2025). Sex hormones and metabolic dysfunction-associated steatotic liver disease. International Journal of Molecular Sciences, 26(19), 9594.

Jamalinia, M., Zare, F., Mantovani, A., Targher, G., & Lonardo, A. (2025). Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: A meta-analysis. Diabetes, Obesity and Metabolism, 27(9), e16568.

Lonardo, A., & Weiskirchen, R. (2025). Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: A novel star on the horizon? Exploration of Drug Science, 3, 1008128.

Lonardo, A., Zheng, M.-H., & Weiskirchen, R. (2025). Food insecurity is an emerging risk factor for liver disease: A scoping review. Expert Review of Gastroenterology & Hepatology, 19(9), 2545812.

Lonardo, A., & Weiskirchen, R. (2025). PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD. Exploration of Digestive Diseases, 3, 100590.

Lonardo, A., Zheng, M.-H., & Eslam, M. (2025). MASLD vs. MAFLD: A narrative review. Exploration of Digestive Diseases, 3, 100586.

Lonardo, A., Stefan, N., & Mantovani, A. (2025). Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. Trends in Endocrinology & Metabolism, 36(7),

Weiskirchen, R., & Lonardo, A. (2025). The ovary–liver axis: Molecular science and epidemiology. International Journal of Molecular Sciences, 26(13), 6382.